Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of “Buy” by Brokerages

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have been given an average rating of “Buy” by the five analysts that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $16.00.

A number of research analysts recently issued reports on TENX shares. William Blair initiated coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating for the company. Guggenheim assumed coverage on shares of Tenax Therapeutics in a research report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price for the company. Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Leerink Partners started coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price on the stock. Finally, StockNews.com started coverage on Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating on the stock.

Hedge Funds Weigh In On Tenax Therapeutics

Large investors have recently made changes to their positions in the company. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics in the third quarter valued at about $101,000. Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics in the 3rd quarter valued at $173,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Tenax Therapeutics during the third quarter valued at about $288,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $6.24 on Wednesday. The firm has a 50 day moving average price of $5.56 and a 200 day moving average price of $4.35. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $21.46.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.